[250 Pages Report] During the forecast period, the artificial pancreas device system market is expected to advance at a rapid pace with a CAGR of 18.2%.
The soaring incidence of diabetes, intense R&D efforts by players in the industry, and growing adoption for automated systems for glycemic control are the contributing factors growth of the market. Artificial pancreas device systems (APDS) regulate blood glucose levels in diabetic patients, and industry participants are conducting numerous studies to improve diabetes management. These devices are much less invasive and thus widely used by patients. The growing geriatric population, rising diabetes incidence, and rising obesity prevalence are all driving artificial pancreas device system market growth.
Bionic Pancreas system, technological advancements such as in-home use of Bionic Pancreas system is also expected to create significant opportunities for expansion in the near future. Furthermore, increased awareness of APDS and their use has resulted in artificial pancreas device system market growth in both developed and developing countries.
APDS can eliminate the need for frequent sugar level checks. Furthermore, increased global teleconsultancy activity for follow-up and routine check-ups during the pandemic is likely to boost artificial pancreas device system market growth for point-of-care technologies such as APDS. As a result, the trends are expected to have a significant impact on the adoption of APDS in the coming years.
One of the key factors driving the artificial pancreas device system market growth is the rising prevalence of diabetes due to ageing, obesity, and an unhealthy lifestyle. One of the most important factors driving the expansion of the artificial pancreas device system market artificial pancreas device system market is the rising prevalence of diabetes due to ageing, obesity, and an unhealthy lifestyle.
The threshold suspended device system helps to reverse or lessen the severity of a dangerous drop in blood glucose level (hypoglycaemia) by temporarily suspending insulin delivery when the glucose level falls to or approaches a low glucose threshold. These are also known as low glucose suspends systems. The regulation of glucose in diabetic patients is critical for improved health outcomes. As a result, threshold suspended device systems play an important role in hypoglycaemia management. Product innovations, increased product approvals, and partnerships and collaborations by key players all contribute to artificial pancreas device system market growth.
The United States dominated the artificial pancreas device system market, accounting for 88.50% of the total. High per capita income and rising healthcare spending are two key factors driving the global artificial pancreas device system market. Furthermore, smart device adoption and technological advancements such as the use of AI and data analytics are propelling industry growth. According to the International Diabetes Federation, one out of every eight adults has impaired blood glucose tolerance. During the forecast period, this ratio is expected to rise even further.
North America controlled the artificial pancreas device system market and had the highest revenue share. The region is also expected to be driven by rising obesity rates, the presence of efficient reimbursement policies, and increased awareness of advanced diabetes management technologies. Additionally, the presence of prominent players, high treatment costs, technological advancement, and product launches are expected to propel the regional market. Furthermore, the growing diabetic population has prompted private and public organisations to invest in diabetes research. These factors are expected to increase APDS adoption in the region.
To strengthen their market position, key artificial pancreas device system market players are implementing strategies such as mergers and acquisitions, partnerships, and the launch of new technologically advanced products and services. They are heavily investing in R&D activities in order to produce technologically advanced products.
Medtronic, for example, received CE-Mark for its MiniMed 780G in June 2020. The device automatically adjusts basal insulin rates every five minutes and is appropriate for diabetic patients aged 7 to 80. Similarly, the FDA in the United States approved a next-generation hybrid closed-loop insulin delivery system for children aged 2 to 6 years with type 1 diabetes in September 2020.
DexCom, Inc. acquired Type Zero Technologies, Inc., a company that invented a system that could monitor and regulate insulin delivery from insulin pumps, thereby trying to position itself in the artificial pancreas technology market and raising the arificial pancreas device systems.
| Attributes | Details |
|---|---|
| Artificial Pancreas Device System Market CAGR | 18.2% |
| Artificial Pancreas Device System Market (2025) | US$ 2.1 Billion |
Sales of artificial pancreas device systems are expected to rise as they are used in the treatment of Type 1 diabetes, which requires multiple doses of insulin in a day and all-round the year and with rising diabetes cases across the globe.
In addition to this, demand for artificial pancreas device systems rises as it plays a crucial role in glucose control in diabetic patients for a better health outcome.
Control algorithm software in an external controller performs mathematical calculations to send dosing instructions to the insulin infusion pumps or computer and this feature likely drives the demand for artificial pancreas device systems.
Demand for artificial pancreas device systems is also expected to be fuelled by rising investments in R&D activities by major players to expand their artificial pancreas device system market share.
Furthermore, the increased demand for automated systems that control glucose levels due to their flexibility, accuracy, and ease of use drives the sales of artificial pancreas device systems in coming years.
Soaring demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also fuelling the sales of artificial pancreas device systems.
Various technological advancements, such as the development of software-based wireless systems integrated with automated controls, are also contributing to the higher demand for artificial pancreas device systems.
Furthermore, an increase in the demand for computerised glycemic control systems, the presence of a large population of children and elderly within the target customer group is propelling the sales of artificial pancreas device systems.
Demand for artificial pancreas device systems spikes as diabetes management technologies, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems, have advanced in recent years.
CGM advancements elicited a paradigm shift in the management of type 1 diabetes which is anticipated to bring about huge sales of artificial pancreas device systems, in turn, propelling the artificial pancreas device system market growt
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Food and Drug Administration (FDA) is collaborating with private and government research institutions to improvise clinical studies and accelerate the development and demand for artificial pancreas device systems.
The FDA released a document on requirements of clinical studies and premarket approval applications for the production of artificial pancreas device systems. This will encourage the manufacturers to expand their artificial pancreas device system market share.
These devices cater to the need of calibrating the continuous glucose monitor at equal intervals and drive the demand for artificial pancreas device systems.
Also, sales of artificial pancreas device systems spike as the continuous glucose monitoring sensors are subjected to biofouling and fibrosis when they are placed subcutaneously which alters the productivity of sensors.
The FDA has identified issues in the components and software of insulin infusion pumps. The insulin used currently in the artificial pancreas device systems takes a longer duration of time to completely absorb.
Such factors related to artificial pancreas device systems could potentially hamper the demand for artificial pancreas device systems and the growth of the global artificial pancreas device system market.
Depending on geographic regions, the global Artificial Pancreas Device System market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan, and Middle East & Africa.
During the forecast period, Asia Pacific is expected to grow the fastest and elicit greater demand for artificial pancreas device systems.
Sales of artificial pancreas device systems are on the rise as well on account of changes in lifestyle, genetic modification, urbanisation, aging, etc.
Diabetes incidences are expected to rise during the forecast period in the region, in turn, supporting artificial pancreas device system market growth and increasing the demand for artificial pancreas device systems.
India, China, the USA, Indonesia, Pakistan, and Japan are the top six countries with the highest number of estimated cases of diabetes and large artificial pancreas device system market share.
As a result, the Asia Pacific and North America are anticipated to be the potential markets for the global artificial pancreas device system market players.
Europe is also expected to witness high sales of artificial pancreas device systems due to the presence of sophisticated healthcare infrastructure, high levels of patient awareness, and relatively higher levels of healthcare expenditure.
Furthermore, funds provided by the government to improve treatment quality are encouraging industry players and researchers to bring in new technology thereby surging the demand for artificial pancreas device systems.
Principal Consultant
Some of the key market players in the global artificial pancreas device system market are Pancreum, LLC, Medtronic, Inc., and JDRF.
In the near future, the global artificial pancreas device system manufacturers are likely to develop products that will not only monitor but also adjust the blood glucose levels rapidly without the need for intervention of the patient.
Such steps are anticipated to consolidate their position in the market by enlarging their artificial pancreas device system market share and the same augments the sales of artificial pancreas device systems.
The major players are pursuing a variety of strategies, including R&D investment, collaborations, and acquisitions in order to expand their artificial pancreas device system market share.
DexCom, Inc. acquired Type Zero Technologies, Inc., a company that designed a system to manage and regulate insulin delivery from insulin pumps, thereby positioning itself in the artificial pancreas technology market and this also raises the arificial pancreas device systems.
| Report Attributes | Details |
|---|---|
| Growth rate | CAGR of 18.2% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in US$ million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Product, application, region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Pancreum, LLC; Medtronic, Inc. and JDRF; Johnson & Johnson; Beta Bionics, Inc.; Tandem Diabetes Care and others. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market is likely to register a CAGR of 18.2% through 2032.
The market is currently valued at US$ 2.1 Bn in 2025.
North America is likely to be a leading market during the forecast period.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Type, 2022-2032 5.3.1. Threshold Suspended Device System 5.3.2. Insulin-Only System 5.3.3. Bi-Hormonal Control System 5.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 6.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021 7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. East Asia 7.3.5. South Asia & Pacific 7.3.6. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Type 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Type 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Type 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Type 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By End User 10.4. Key Takeaways 11. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.2. By Type 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By End User 11.4. Key Takeaways 12. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Thailand 12.2.1.3. Indonesia 12.2.1.4. Malaysia 12.2.1.5. Singapore 12.2.1.6. Australia 12.2.1.7. New Zealand 12.2.1.8. Rest of South Asia & Pacific 12.2.2. By Type 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By End User 12.4. Key Takeaways 13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Type 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By End User 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Type 14.1.2.2. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Type 14.2.2.2. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Type 14.3.2.2. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Type 14.4.2.2. By End User 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Type 14.5.2.2. By End User 14.6. U.K. 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Type 14.6.2.2. By End User 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Type 14.7.2.2. By End User 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Type 14.8.2.2. By End User 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Type 14.9.2.2. By End User 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Type 14.10.2.2. By End User 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Type 14.11.2.2. By End User 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Type 14.12.2.2. By End User 14.13. India 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Type 14.13.2.2. By End User 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Type 14.14.2.2. By End User 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Type 14.15.2.2. By End User 14.16. Malaysia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Type 14.16.2.2. By End User 14.17. Singapore 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2021 14.17.2.1. By Type 14.17.2.2. By End User 14.18. Australia 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2021 14.18.2.1. By Type 14.18.2.2. By End User 14.19. New Zealand 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2021 14.19.2.1. By Type 14.19.2.2. By End User 14.20. GCC Countries 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2021 14.20.2.1. By Type 14.20.2.2. By End User 14.21. South Africa 14.21.1. Pricing Analysis 14.21.2. Market Share Analysis, 2021 14.21.2.1. By Type 14.21.2.2. By End User 14.22. Israel 14.22.1. Pricing Analysis 14.22.2. Market Share Analysis, 2021 14.22.2.1. By Type 14.22.2.2. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Type 15.3.3. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Pancreum, LLC 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.1.5.2. Product Strategy 16.1.1.5.3. Channel Strategy 16.1.2. Medtronic, Inc. 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.2.5.2. Product Strategy 16.1.2.5.3. Channel Strategy 16.1.3. JDRF 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.3.5.2. Product Strategy 16.1.3.5.3. Channel Strategy 16.1.4. Johnson & Johnson 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.4.5.2. Product Strategy 16.1.4.5.3. Channel Strategy 16.1.5. Beta Bionics, Inc. 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.5.5.2. Product Strategy 16.1.5.5.3. Channel Strategy 16.1.6. Tandem Diabetes Care 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.6.5.2. Product Strategy 16.1.6.5.3. Channel Strategy 16.1.7. Insulet Corporation 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.7.5.2. Product Strategy 16.1.7.5.3. Channel Strategy 16.1.8. Bigfoot Biomedical, Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.8.5.2. Product Strategy 16.1.8.5.3. Channel Strategy 16.1.9. Dexcom, Inc. 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.9.5.2. Product Strategy 16.1.9.5.3. Channel Strategy 16.1.10. Admetsys 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 16.1.10.5.2. Product Strategy 16.1.10.5.3. Channel Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Healthcare
March 2017
REP-NA-3058
121 pages
Explore Healthcare Insights
View Reports
Artificial Pancreas Device System Market
